Base de dados : MEDLINE
Pesquisa : D02.705.672.875 [Categoria DeCS]
Referências encontradas : 2272 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 228 ir para página                         

  1 / 2272 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27771496
[Au] Autor:Cabrero M; Martin A; Briones J; Gayoso J; Jarque I; López J; Grande C; Heras I; Arranz R; Bernal T; Perez-Lopez E; López-Godino O; Conde E; Caballero D
[Ad] Endereço:Hematology Department, Hospital Universitario Salamanca and IBSAL (Instituto Biosanitario de Salamanca), Spain.
[Ti] Título:Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial.
[So] Source:Biol Blood Marrow Transplant;23(1):53-59, 2017 Jan.
[Is] ISSN:1523-6536
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:We designed a phase II clinical trial including Y-90 ibritumomab-tiuxetan as part of a reduced-intensity conditioning (RIC) allogeneic stem cell transplantation (AlloSCT) in high-risk non-Hodgkin lymphoma (Clinical Trials Identifier: NCT00644371). Eligible patients had high-risk relapsed/refractory aggressive lymphoma. The conditioning regimen consisted of rituximab 250 mg (days -21 and -14), Y-90 ibritumomab IV (.4 m Ci/kg, day -14), fludarabine 30 mg/m i.v. (days -3 and -2) plus melphalan 70 mg/m i.v. (days -3 and -2) or 1 dose of melphalan and thiotepa 5 mg/kg (day -8). Donors were related. Eighteen patients were evaluable. At the time of transplantation, responses were complete remission (CR) (n = 7, 39%), partial remission (n = 6, 33%) or refractory disease (n = 4, 28%). Y-90-ibritumomab infusions were well tolerated, with no adverse reactions. Nonrelapse mortality at 1 year was 28%. Median follow-up was 46 (range, 39 to 55) months. Estimated 1-year progression-free survival (PFS) was 50%, and 4-year overall survival (OS) and PFS were both 44.4%. CR at the moment of AlloSCT had significant impact on PFS (71% versus 27%, P = .046) and OS (71% versus 27%, P = .047). Our results show that Y-90-ibritumomab-tiuxetan as a component of RIC for AlloSCT is feasible in patients with high-risk B cell lymphoma. Development of phase III clinical trials is needed to clarify the contribution of radioimmunotherapy to RIC AlloSCT.
[Mh] Termos MeSH primário: Anticorpos Monoclonais/administração & dosagem
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Linfoma de Células B/terapia
Terapia de Salvação/métodos
Condicionamento Pré-Transplante/métodos
[Mh] Termos MeSH secundário: Adulto
Feminino
Transplante de Células-Tronco Hematopoéticas/métodos
Transplante de Células-Tronco Hematopoéticas/mortalidade
Seres Humanos
Linfoma de Células B/mortalidade
Masculino
Melfalan/administração & dosagem
Meia-Idade
Radioimunoterapia/métodos
Radioimunoterapia/mortalidade
Terapia de Salvação/mortalidade
Análise de Sobrevida
Tiotepa/administração & dosagem
Condicionamento Pré-Transplante/mortalidade
Transplante Homólogo
Vidarabina/administração & dosagem
Vidarabina/análogos & derivados
Radioisótopos de Ítrio/uso terapêutico
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE II; JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Antibodies, Monoclonal); 0 (Yttrium Radioisotopes); 4Q52C550XK (ibritumomab tiuxetan); 905Z5W3GKH (Thiotepa); FA2DM6879K (Vidarabine); P2K93U8740 (fludarabine); Q41OR9510P (Melphalan)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE


  2 / 2272 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29173979
[Au] Autor:Simon N; Coiteux V; Bruno B; Taque S; Charbonnier A; Souchet L; Vincent L; Yakoub-Agha I; Chalandon Y
[Ad] Endereço:Université de Lille, EA 7365, GRITA, groupe de recherche sur les formes injectables et les technologies associées, 59000 Lille, France; CHU de Lille, institut de pharmacie, 59000 Lille, France.
[Ti] Título:[Dose adaptation of the drugs used for hematopoietic stem-cell transplantation in patients with comorbidity: Obesity, chronic renal disease or hepatopathy: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
[Ti] Título:Adaptation des doses de médicament des conditionnements de greffe de cellules souches hématopoïétiques dans des populations avec comorbidité : obésité, maladie rénale chronique ou hépatopathie : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC)..
[So] Source:Bull Cancer;104(12S):S99-S105, 2017 Dec.
[Is] ISSN:1769-6917
[Cp] País de publicação:France
[La] Idioma:fre
[Ab] Resumo:In September 2016 in Lille, France, the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) organized the 7th Allogeneic Stem Cell Transplantation Clinical Practices Harmonization Workshop Series. Our work group focused on chemotherapy drug dose adaptation for hematopoietic stem cell transplantation patients presenting a comorbidity. The purpose of this workshop was to provide recommendations on chemotherapy drug dose adaptation for patient populations receiving hematopoietic stem cell transplantation who also had the following comorbidities: obesity, chronic kidney disease and hepatopathy.
[Mh] Termos MeSH primário: Transplante de Células-Tronco Hematopoéticas/normas
Imunossupressores/administração & dosagem
Hepatopatias
Obesidade
Insuficiência Renal Crônica
Condicionamento Pré-Transplante/normas
[Mh] Termos MeSH secundário: Adulto
Fatores Etários
Bussulfano/administração & dosagem
Criança
Comorbidade
Ciclofosfamida/administração & dosagem
Etoposídeo/administração & dosagem
França
Seres Humanos
Hepatopatias/epidemiologia
Melfalan/administração & dosagem
Obesidade/epidemiologia
Insuficiência Renal Crônica/epidemiologia
Sociedades Médicas
Inquéritos e Questionários
Tiotepa/administração & dosagem
Vidarabina/administração & dosagem
Vidarabina/análogos & derivados
Irradiação Corporal Total
[Pt] Tipo de publicação:CONSENSUS DEVELOPMENT CONFERENCE; JOURNAL ARTICLE; PRACTICE GUIDELINE; REVIEW
[Nm] Nome de substância:
0 (Immunosuppressive Agents); 6PLQ3CP4P3 (Etoposide); 8N3DW7272P (Cyclophosphamide); 905Z5W3GKH (Thiotepa); FA2DM6879K (Vidarabine); G1LN9045DK (Busulfan); P2K93U8740 (fludarabine); Q41OR9510P (Melphalan)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171228
[Lr] Data última revisão:
171228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171128
[St] Status:MEDLINE


  3 / 2272 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28905508
[Au] Autor:Osorio DS; Dunkel IJ; Cervone KA; Goyal RK; Steve Lo KM; Finlay JL; Gardner SL
[Ad] Endereço:Nationwide Children's Hospital, Ohio State University, Columbus, Ohio.
[Ti] Título:Tandem thiotepa with autologous hematopoietic cell rescue in patients with recurrent, refractory, or poor prognosis solid tumor malignancies.
[So] Source:Pediatr Blood Cancer;65(1), 2018 Jan.
[Is] ISSN:1545-5017
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The purpose of this study was to determine the feasibility and tolerability of tandem courses of high-dose thiotepa with autologous hematopoietic cell rescue (AHCR) in patients with recurrent, refractory solid tumors who were ineligible for a single course of high-dose therapy due to greater than minimal residual disease. Patients with decreased hearing or poor renal function were eligible. PROCEDURE: Thiotepa was administered intravenously at a dose of 200 mg/m /day (6.67 mg/kg/day) daily for 3 days followed by AHCR. A second course of thiotepa was given 4 weeks later provided blood counts recovered sufficiently without evidence of tumor progression. RESULTS: Fifty-eight patients received 96 courses. Thirty-eight (65%) patients received two courses of therapy. Twenty-seven courses (28%) were administered completely in the outpatient setting. A toxic mortality rate of 3.4% was observed. Five of 26 patients with medulloblastoma were alive at a median of 35 months, whereas 21 patients died at a median of 11.7 months. Four of five patients with central nervous system germ cell tumors (CNS GCT) were alive 68-103 months following AHCR. CONCLUSIONS: Two cycles of high-dose thiotepa with AHCR were well tolerated even in these heavily pretreated patients. This therapy may provide prolonged survival in patients with recurrent malignant brain tumors, particularly medulloblastoma and CNS GCT.
[Mh] Termos MeSH primário: Neoplasias Encefálicas
Transplante de Células-Tronco Hematopoéticas
Meduloblastoma
Tiotepa/administração & dosagem
[Mh] Termos MeSH secundário: Adolescente
Adulto
Autoenxertos
Neoplasias Encefálicas/mortalidade
Neoplasias Encefálicas/terapia
Criança
Pré-Escolar
Intervalo Livre de Doença
Feminino
Seres Humanos
Lactente
Masculino
Meduloblastoma/mortalidade
Meduloblastoma/terapia
Taxa de Sobrevida
Tiotepa/efeitos adversos
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
905Z5W3GKH (Thiotepa)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171129
[Lr] Data última revisão:
171129
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170915
[St] Status:MEDLINE
[do] DOI:10.1002/pbc.26776


  4 / 2272 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28901730
[Au] Autor:Rastogi N; Katewa S; Thakkar D; Kohli S; Nivargi S; Yadav SP
[Ad] Endereço:Pediatric Hematology Oncology Unit, Department of Pediatrics, Fortis Memorial Research Institute, Gurgaon, Haryana, India.
[Ti] Título:Reduced-toxicity alternate-donor stem cell transplantation with posttransplant cyclophosphamide for primary immunodeficiency disorders.
[So] Source:Pediatr Blood Cancer;65(1), 2018 Jan.
[Is] ISSN:1545-5017
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:We describe here the outcomes of reduced-toxicity alternate-donor stem cell transplant (SCT) with posttransplant cyclophosphamide (PTCy) for primary immunodeficiency disorders (PIDs) in eight children (haploidentical-seven and matched unrelated donor-one). The conditioning was with serotherapy (alemtuzumab-3/rabbit-anti-thymoglobulin-5); fludarabine, cyclophosphamide, and total body irradiation-5 (additional thiotepa-3); fludarabine and treosulfan-2; and fludarabine and busulfan-1. All received PTCy 50 mg/kg on days 3 and 4 as graft versus host disease prophylaxis along with tacrolimus and mycophenolate. Mean CD34 dose was 13.8 × 10 /kg. Two children died because of PIDs. Acute graft versus host disease up to grades I and II was seen in three children. All six survivors are fully donor and disease free at median follow-up of 753 days. Alternate donor SCT with PTCy is feasible in PID and has good outcomes.
[Mh] Termos MeSH primário: Ciclofosfamida/administração & dosagem
Síndromes de Imunodeficiência/terapia
Transplante de Células-Tronco de Sangue Periférico
Condicionamento Pré-Transplante
Doadores não Relacionados
[Mh] Termos MeSH secundário: Alemtuzumab/administração & dosagem
Aloenxertos
Soro Antilinfocitário/administração & dosagem
Criança
Pré-Escolar
Intervalo Livre de Doença
Seguimentos
Seres Humanos
Síndromes de Imunodeficiência/mortalidade
Lactente
Masculino
Taxa de Sobrevida
Tiotepa/administração & dosagem
Irradiação Corporal Total
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antilymphocyte Serum); 3A189DH42V (Alemtuzumab); 8N3DW7272P (Cyclophosphamide); 905Z5W3GKH (Thiotepa); D7RD81HE4W (thymoglobulin)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171129
[Lr] Data última revisão:
171129
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170914
[St] Status:MEDLINE
[do] DOI:10.1002/pbc.26783


  5 / 2272 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28614903
[Au] Autor:Eder S; Canaani J; Beohou E; Labopin M; Sanz J; Arcese W; Or R; Finke J; Cortelezzi A; Beelen D; Passweg J; Socié G; Gurman G; Aljurf M; Stelljes M; Giebel S; Mohty M; Nagler A
[Ad] Endereço:EBMT Office Paris, Hôpital Saint-Antoine, Paris, France.
[Ti] Título:Thiotepa-based conditioning versus total body irradiation as myeloablative conditioning prior to allogeneic stem cell transplantation for acute lymphoblastic leukemia: A matched-pair analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
[So] Source:Am J Hematol;92(10):997-1003, 2017 Oct.
[Is] ISSN:1096-8652
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The optimal conditioning regimen to employ before hematopoietic stem cell transplantation in acute lymphoblastic leukemia (ALL) is still undecided, and while cyclophosphamide/total body irradiation (Cy/TBI) is the most commonly used myeloablative regimen, there are concerns regarding long-term toxicity for patients conditioned with this regimen. Thiotepa-based conditioning is an emerging radiation-free regimen with recent publications indicative of comparable clinical outcomes to TBI-based conditioning. In this analysis of the acute leukemia working party of the EBMT, we performed a retrospective matched-pair analysis, evaluating the outcome of adult patients with ALL who received thiotepa-based conditioning (n = 180) with those receiving Cy/TBI conditioning (n = 540). The 2-year leukemia-free survival and overall survival (OS) rates of both conditioning regimens were comparable, 33% for thiotepa [95% confidence interval (CI): 26.4-42.8] versus 39% for Cy/TBI (95% CI: 34.8-44.5] (P = .33) and 46.5% [95% CI: 38.6-56.1] versus 48.8% [95% CI: 44.2-54] (P = .9), respectively. There was no significant difference between the two regimens in the incidence of either acute graft versus host disease (GVHD) or chronic GVHD. Multivariate analysis demonstrated increased relapse incidence for thiotepa conditioning compared to Cy/TBI (HR = 1.78, 95% CI, 1.07-2.95; P = .03) which did not affect OS. Our results indicate that thiotepa-based conditioning may not be inferior to Cy/TBI for adult patients with ALL.
[Mh] Termos MeSH primário: Transplante de Células-Tronco Hematopoéticas/métodos
Agonistas Mieloablativos/administração & dosagem
Leucemia-Linfoma Linfoblástico de Células Precursoras/terapia
Tiotepa/administração & dosagem
Condicionamento Pré-Transplante/métodos
Irradiação Corporal Total
[Mh] Termos MeSH secundário: Adolescente
Adulto
Ciclofosfamida/administração & dosagem
Intervalo Livre de Doença
Feminino
Seres Humanos
Masculino
Meia-Idade
Análise Multivariada
Leucemia-Linfoma Linfoblástico de Células Precursoras/mortalidade
Recidiva
Estudos Retrospectivos
Taxa de Sobrevida
Transplante Homólogo
Adulto Jovem
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Myeloablative Agonists); 8N3DW7272P (Cyclophosphamide); 905Z5W3GKH (Thiotepa)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170925
[Lr] Data última revisão:
170925
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170615
[St] Status:MEDLINE
[do] DOI:10.1002/ajh.24823


  6 / 2272 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28509337
[Au] Autor:Szychot E; Seunarine K; Mankad K; Thust S; Clark C; Gaze MN; Michalski A
[Ad] Endereço:Department of Clinical Studies, The Institute of Cancer Research, London, United Kingdom.
[Ti] Título:Impact of induction chemotherapy, hyperfractionated accelerated radiotherapy and high-dose thiotepa on brain volume loss and functional status of children with primitive neuroectodermal tumour.
[So] Source:Pediatr Blood Cancer;64(11), 2017 Nov.
[Is] ISSN:1545-5017
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The introduction of aggressive chemo-radiotherapy regimens has improved overall survival in children with primitive neuroectodermal tumours (PNET). However, these combinations may result in neurotoxicity. Previously reported magnetic resonance imaging abnormalities in children receiving intensive sequential chemotherapy, hyperfractionated accelerated radiotherapy (HART) and high-dose thiotepa prompted us to investigate the degree of brain volume loss and patients' functional status after therapy. METHODS: We retrospectively reviewed clinico-radiological data of children with PNET treated in this way at our centre. RESULTS: We studied 14 children treated between December 2009 and April 2013. Data were not complete for one child. Performance status was severely restricted in four children, and mildly to moderately impaired in 7 of the 13 children. Eleven of 13 children showed mild-to-severe generalised neuroparenchymal atrophy, in 7 of whom neuroparenchymal volume loss was moderate to severe. Of these seven, six had received high-dose thiotepa. There was no correlation between brain volume loss and Lansky performance status. However, unexpected neurotoxicities, such as symptoms of transverse myelitis, were observed. CONCLUSION: Measurement of brain volume loss in patients treated with HART and high-dose thiotepa may not be sufficient to predict function. However, correlation of brain volume loss due to late neurotoxicity with performance decline may be more obvious over longer period of follow-up. The combination of HART and myeloablative courses of thiotepa is associated with severe neurotoxicity and subsequent decline in performance status in a significant proportion of patients.
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Neoplasias Encefálicas/patologia
Quimiorradioterapia
Quimioterapia de Indução
Tumores Neuroectodérmicos Primitivos/patologia
[Mh] Termos MeSH secundário: Adolescente
Neoplasias Encefálicas/terapia
Carboplatina/administração & dosagem
Criança
Pré-Escolar
Ciclofosfamida/administração & dosagem
Fracionamento de Dose
Etoposídeo/administração & dosagem
Feminino
Seguimentos
Seres Humanos
Masculino
Estadiamento de Neoplasias
Tumores Neuroectodérmicos Primitivos/terapia
Prognóstico
Estudos Retrospectivos
Taxa de Sobrevida
Tiotepa/administração & dosagem
Carga Tumoral
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
6PLQ3CP4P3 (Etoposide); 8N3DW7272P (Cyclophosphamide); 905Z5W3GKH (Thiotepa); BG3F62OND5 (Carboplatin)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171031
[Lr] Data última revisão:
171031
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170517
[St] Status:MEDLINE
[do] DOI:10.1002/pbc.26619


  7 / 2272 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28369839
[Au] Autor:DeFilipp Z; Li S; El-Jawahri A; Armand P; Nayak L; Wang N; Batchelor TT; Chen YB
[Ad] Endereço:Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, Massachusetts.
[Ti] Título:High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission.
[So] Source:Cancer;123(16):3073-3079, 2017 Aug 15.
[Is] ISSN:1097-0142
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: High-dose chemotherapy and autologous stem cell transplantation (HDC-ASCT) is a therapeutic option for patients with primary central nervous system lymphoma (PCNSL). To the authors' knowledge, data are limited regarding its use among patients in first complete remission (CR1) with the CNS-directed conditioning regimen of thiotepa, busulfan, and cyclophosphamide (TBC). METHODS: A retrospective analysis of patients with PCNSL in CR1 who underwent transplantation using a TBC-based conditioning regimen at 2 academic institutions was performed. RESULTS: Forty-six consecutive patients who underwent HDC-ASCT while in CR1 were identified. The most common induction regimen was high-dose methotrexate plus temozolomide and rituximab (59%). No patients received whole-brain radiotherapy. A total of 40 patients (87%) received cytarabine before undergoing ASCT as either induction intensification, early consolidation therapy, or mobilization. The median time from diagnosis to transplantation was 6 months (range, 4-15 months). The median age of the patients at the time of transplantation was 59 years (range, 27-69 years). With a median follow-up of 2.7 years after ASCT (range, 6 months-7.5 years), the Kaplan-Meier estimates of 2-year overall survival and progression-free survival were 95% (95% confidence interval [95% CI], 80%-99%) and 92% (95% CI, 77%-97%), respectively. The most common toxicities were severe mucositis (35%) and bacterial infections occurring within 100 days of transplantation (35%). The estimated 2-year nonrecurrence mortality rate was 2.9% (95% CI, 0.2%-13.4%). CONCLUSIONS: HDC-ASCT with a CNS-directed conditioning regimen such as TBC should be considered for patients with PCNSL who are in CR1 because this approach is associated with encouraging disease control and survival in this select patient population. Cancer 2017;123:3073-79. © 2017 American Cancer Society.
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Neoplasias do Sistema Nervoso Central/terapia
Linfoma/terapia
Transplante de Células-Tronco/métodos
[Mh] Termos MeSH secundário: Adulto
Idoso
Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos
Infecções Bacterianas/etiologia
Bussulfano/administração & dosagem
Ciclofosfamida/administração & dosagem
Citarabina/administração & dosagem
Dacarbazina/administração & dosagem
Dacarbazina/análogos & derivados
Intervalo Livre de Doença
Feminino
Seguimentos
Seres Humanos
Estimativa de Kaplan-Meier
Masculino
Metotrexato/administração & dosagem
Meia-Idade
Mucosite/etiologia
Indução de Remissão
Estudos Retrospectivos
Rituximab/administração & dosagem
Transplante de Células-Tronco/efeitos adversos
Tiotepa/administração & dosagem
Condicionamento Pré-Transplante
Transplante Autólogo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
04079A1RDZ (Cytarabine); 4F4X42SYQ6 (Rituximab); 7GR28W0FJI (Dacarbazine); 8N3DW7272P (Cyclophosphamide); 905Z5W3GKH (Thiotepa); G1LN9045DK (Busulfan); YF1K15M17Y (temozolomide); YL5FZ2Y5U1 (Methotrexate)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170911
[Lr] Data última revisão:
170911
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170404
[St] Status:MEDLINE
[do] DOI:10.1002/cncr.30695


  8 / 2272 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28214007
[Au] Autor:Boudin L; Chabannon C; Sfumato P; Sabatier R; Bertucci F; Tarpin C; Provansal M; Houvenaeghel G; Lambaudie E; Tallet A; Resbeut M; Charafe-Jauffret E; Calmels B; Lemarie C; Boher JM; Extra JM; Viens P; Gonçalves A
[Ad] Endereço:Institut Paoli-Calmettes (IPC), département d'oncologie médicale, 232, boulevard de Sainte-Marguerite, 13009 Marseille cedex 9, France.
[Ti] Título:[Impact of Her2 and BRCA1/2 status in high-dose chemotherapy and autologous stem cells transplantation in the treatment of breast cancer: The Institut Paoli Calmettes' experience].
[Ti] Título:Expérience de l'institut Paoli-Calmettes concernant la chimiothérapie à haute dose et autogreffe de cellules souches hématopoïétiques pour la prise en charge des cancers mammaires : impact du statut Her2 et BRCA1/2..
[So] Source:Bull Cancer;104(4):332-343, 2017 Apr.
[Is] ISSN:1769-6917
[Cp] País de publicação:France
[La] Idioma:fre
[Ab] Resumo:INTRODUCTION: Studies evaluating chemotherapy high dose chemotherapy with autologous haematopoietic stem cell transplantation (HDC-ACSH) in the treatment of metastatic (MBC), locally advanced (LABC) and inflammatory (IBC) breast cancer have in common lack of biomarker information, in particular the HER2 status. PATIENTS AND METHODS: All consecutive female patients treated for breast cancer with HDC and AHSCT at Institut Paoli Calmettes between 2003 and 2012 were included. Patients were categorized in three subtypes based on hormonal receptor (HR) and HER2 status of the primary tumor: luminal, (HR+/HER2-), HER2 (HER2+, any HR) and triple negative (TN) (HER2- and HR-). The main objective was the analysis of overall survival (OS) according to the IHC subtypes. RESULTS: Three hundred and seventy-seven patients were included. For MBC, the TN subtype appeared to have the worst prognosis with a median OS of 19.68 months (95 % CI 11.76-44.4) compared to 44.64 months (95 % CI 40.32-67.56) for the luminal subtype and a median OS not reached for the HER2 subtype (P<0.01). For IBC, HER2 subgroup appeared to have the best prognosis with a 5-year OS of 89 % (95 % CI 64-97) compared to 57 % (95 % CI 33-76) for the TN subgroup (HR 5.38, 95 % CI 1.14-25.44; P=0.034). For CSLA, luminal subgroup appeared to have the best prognosis with a 5-year OS of 92 % (95 % CI 71-98) against 75 % (95 % CI 46-90) for HER 2 subtype and 70 % (95 %CI 97-88) for TN subtype (P=0.301). CONCLUSION: The HDC-ACSH does not change the prognosis value of IHC subtype in breast cancer patients.
[Mh] Termos MeSH primário: Antineoplásicos/administração & dosagem
Neoplasias da Mama/mortalidade
Genes BRCA1
Genes BRCA2
Genes erbB-2
Transplante de Células-Tronco Hematopoéticas
[Mh] Termos MeSH secundário: Adulto
Idoso
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Autoenxertos
Neoplasias da Mama/tratamento farmacológico
Neoplasias da Mama/patologia
Neoplasias da Mama/cirurgia
Institutos de Câncer
Carcinoma/tratamento farmacológico
Carcinoma/mortalidade
Carcinoma/secundário
Carcinoma/cirurgia
Terapia Combinada/métodos
Ciclofosfamida/administração & dosagem
Feminino
Seres Humanos
Melfalan/administração & dosagem
Meia-Idade
Mitoxantrona/administração & dosagem
Prognóstico
Estudos Retrospectivos
Tiotepa/administração & dosagem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 8N3DW7272P (Cyclophosphamide); 905Z5W3GKH (Thiotepa); BZ114NVM5P (Mitoxantrone); Q41OR9510P (Melphalan)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170421
[Lr] Data última revisão:
170421
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170219
[St] Status:MEDLINE


  9 / 2272 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28165611
[Au] Autor:Lehmann V; Tuinman MA; Keim MC; Winning AM; Olshefski RS; Bajwa RPS; Hagedoorn M; Gerhardt CA
[Ad] Endereço:Center for Biobehavioral Health, The Research Institute at Nationwide Children's Hospital, Columbus, Ohio.
[Ti] Título:Psychosexual development and satisfaction in long-term survivors of childhood cancer: Neurotoxic treatment intensity as a risk indicator.
[So] Source:Cancer;123(10):1869-1876, 2017 May 15.
[Is] ISSN:1097-0142
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Risk factors for impairment in psychosexual development and satisfaction among adult survivors of childhood cancer are poorly understood. The authors compared psychosexual outcomes between survivors and healthy controls, and tested whether at-risk survivors can be identified by 1) treatment neurotoxicity or 2) diagnosis. METHODS: A total of 144 young adult survivors of childhood cancer and 144 matched controls completed questionnaires regarding psychosexual development, sexual satisfaction, and satisfaction with relationship status. Survivors were aged 20 to 40 years and were 5 to 34 years after diagnosis. Using medical chart data, survivors were divided into non-neurotoxic (48 survivors), low-dose (36 survivors), and high-dose (58 survivors) neurotoxic treatment groups. RESULTS: Apart from having fewer lifetime sex partners, survivors did not appear to differ from controls. However, survivors of brain tumors and any survivor who received high-dose neurotoxic treatment reported the lowest rates of achieving milestones of psychosexual development, whereas sexual and relationship status satisfaction were found to be related to relationship status. Neurotoxic treatment intensity further distinguished between survivors of brain tumors with and without psychosexual impairment. CONCLUSIONS: The intensity of neurotoxic treatment may be a valuable indicator of risk for psychosexual impairment relative to diagnosis alone. Health care providers should assess romantic/sexual problems among survivors at risk and make referrals if needed. Cancer 2017;123:1869-1876. © 2017 American Cancer Society.
[Mh] Termos MeSH primário: Neoplasias/terapia
Síndromes Neurotóxicas/epidemiologia
Satisfação Pessoal
Desenvolvimento Psicossexual
Saúde Reprodutiva
Sobreviventes
[Mh] Termos MeSH secundário: Adulto
Antineoplásicos/efeitos adversos
Neoplasias Encefálicas/terapia
Estudos de Casos e Controles
Irradiação Craniana/efeitos adversos
Citarabina/efeitos adversos
Feminino
Seres Humanos
Injeções Espinhais
Leucemia/terapia
Linfoma/terapia
Masculino
Metotrexato/efeitos adversos
Síndromes Neurotóxicas/etiologia
Orgasmo
Fatores de Risco
Parceiros Sexuais
Inquéritos e Questionários
Tiotepa/efeitos adversos
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 04079A1RDZ (Cytarabine); 905Z5W3GKH (Thiotepa); YL5FZ2Y5U1 (Methotrexate)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170814
[Lr] Data última revisão:
170814
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170207
[St] Status:MEDLINE
[do] DOI:10.1002/cncr.30513


  10 / 2272 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28049229
[Au] Autor:Lee JW; Lim DH; Sung KW; Lee HJ; Yi ES; Yoo KH; Koo HH; Suh YL; Shin HJ
[Ad] Endereço:Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
[Ti] Título:Tandem High-Dose Chemotherapy and Autologous Stem Cell Transplantation for High-Grade Gliomas in Children and Adolescents.
[So] Source:J Korean Med Sci;32(2):195-203, 2017 Feb.
[Is] ISSN:1598-6357
[Cp] País de publicação:Korea (South)
[La] Idioma:eng
[Ab] Resumo:With the aim to investigate the outcome of tandem high-dose chemotherapy and autologous stem cell transplantation (HDCT/auto-SCT) for high-grade gliomas (HGGs), we retrospectively reviewed the medical records of 30 patients with HGGs (16 glioblastomas, 7 anaplastic astrocytomas, and 7 other HGGs) between 2006 and 2015. Gross or near total resection was possible in 11 patients. Front-line treatment after surgery was radiotherapy (RT) in 14 patients and chemotherapy in the remaining 16 patients including 3 patients less than 3 years of age. Eight of 12 patients who remained progression free and 5 of the remaining 18 patients who experienced progression during induction treatment underwent the first HDCT/auto-SCT with carboplatin + thiotepa + etoposide (CTE) regimen and 11 of them proceeded to the second HDCT/auto-SCT with cyclophosphamide + melphalan (CyM) regimen. One patient died from hepatic veno-occlusive disease (VOD) during the second HDCT/auto-SCT; otherwise, toxicities were manageable. Four patients in complete response (CR) and 3 of 7 patients in partial response (PR) or second PR at the first HDCT/auto-SCT remained event free: however, 2 patients with progressive tumor experienced progression again. The probabilities of 3-year overall survival (OS) after the first HDCT/auto-SCT in 11 patients in CR, PR, or second PR was 58.2% ± 16.9%. Tumor status at the first HDCT/auto-SCT was the only significant factor for outcome after HDCT/auto-SCT. There was no difference in survival between glioblastoma and other HGGs. This study suggests that the outcome of HGGs in children and adolescents after HDCT/auto-SCT is encouraging if the patient could achieve CR or PR before HDCT/auto-SCT.
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Neoplasias Encefálicas/tratamento farmacológico
Glioma/tratamento farmacológico
[Mh] Termos MeSH secundário: Adolescente
Neoplasias Encefálicas/mortalidade
Neoplasias Encefálicas/terapia
Carboplatina/administração & dosagem
Criança
Pré-Escolar
Etoposídeo/administração & dosagem
Feminino
Glioma/mortalidade
Glioma/terapia
Seres Humanos
Masculino
Gradação de Tumores
Indução de Remissão
Estudos Retrospectivos
Transplante de Células-Tronco
Taxa de Sobrevida
Tiotepa/administração & dosagem
Transplante Autólogo
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
6PLQ3CP4P3 (Etoposide); 905Z5W3GKH (Thiotepa); BG3F62OND5 (Carboplatin)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170331
[Lr] Data última revisão:
170331
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170104
[St] Status:MEDLINE
[do] DOI:10.3346/jkms.2017.32.2.195



página 1 de 228 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde